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   Prognosis on evaluable 86 patients with primary bladder tumor seen during the 10 years up 
to 1985 was evaluated in relation to treatment mode and tumor stage. The majority of patients 
underwent multimodal therapies including surgery, chemotherapy and immunotherapy with piciba-
nil (0K432). 
   Transurethral resection of the tumor was performed as an initial surgical treatment in 49 pa-
tients, 9 of whom ultimately underwent total cystectomy. After leaving hospital, these patients 
were kept on immunotherapy with OK432 and topical chemotherapy with bladder instillation of 
mitomycin C or adriamycin (ADM) with or without systemic administration of Tegefur as long 
as possible. The overall actual 5-year survival rate for the patients treated by initial transurethral 
resection was 80%. Recurrence rate for these 49 patients was 35%. 
   Total cystectomy with urinary diversion was performed in 37 patients who had been placed 
postoperatively on systemic administration of Tegafur and immunotherapy with OK 432 as long 
as possible. The overall actual 5-year survival rate for the patients treated with total cystectomy 
was 54%. The patients with pT2 and lower stage tumor had an acutual 5 year survival rate of 72 
%, while the patients with pT3 and higher stage tumors had a survival of 10%. 
   The high recurrence rate in the patients with superficial tumor and the low actual survival 
rate of the patients with pT3 and higher stage remain u problem in the treatment of bladder tu-
mor. In recent trials, bacillus Calmette-Guerin instillation therapy has been initiated to lower the 
recurrence rate in superficial tumor and we have had a satisfactory 4-year result. We have also 
begun a multimodal chemotherapy (MVAC) using methotrexate, vinblastin, ADM and cis-dichlo-
rodiamine platinum for patients with advanced bladder tumor and expect longer survival of these 
patients. 
                                                  (Acta Urol. Jpn. 34: 1589-1592, 1988)















































































































































































































































1)松 浦 健,杉 山 高 秀,辻 橋 宏 典,ほ か=膀 胱 腫 瘍















6)小 島 敬 ・ 表 在 性 膀 胱 癌 のBCG膀 胱 内 注 入 に
よ る 治 療,BCG免 疫 療 法 研 究 会 誌7:55・-60,
1983
8)内 田 豊 昭,小 林 健 一,本 田 直 康,ほ か=膀 胱 腫 瘍






9)園 田 孝 夫,ほ か;膀 胱 癌 治 療 一 進 歩,手 術 療 法.
癌 の 臨 床26=752-758,1980
亘0)辻 村 俊 策,加 藤 次 朗,上 田 公 介,ほ か:い わ ゆ る
細 胞 性 免 疫 能 賦 活 剤 を 投 与 し た 膀 胱 腫 瘍 症 例 の 検
討.泌 尿 紀 要9～15,1983
11)TeruoM,HirokiW,TcrufumiFetal.lIm・
munochcmotherapyforadvancedbladder
cancerusingFT-207,adriamycinandOK-
432.TohokuJExpMed138=161・-165,1982
12)SternbergGN,YagodaA,ScherHIeta1=
PreliminaryresultsofM-VAC(Methotrexate,
Vinblastin,doxorubicinandcisplat三n)for
transitionalcellcarcinomaoftheurothc・
lium.Jurol133=403--407,1985
(1987年10月7日 受 付)
